Market Cap (In USD)
9.07 Million
Revenue (In USD)
-
Net Income (In USD)
-23.53 Million
Avg. Volume
-
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.026-0.0392
- PE
- -
- EPS
- -
- Beta Value
- -0.907
- ISIN
- US17248W1137
- CUSIP
- 17248W113
- CIK
- 1862150
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Shane J. Schaffer Pharm.D.
- Employee Count
- -
- Website
- https://www.cingulate.com
- Ipo Date
- Details
- Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of central nervous system and neurobiological disorders. The company's lead product candidates are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of attention deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas with an additional location in Morristown, New Jersey.
More Stocks
-
GTWOG2 Goldfields Inc.
GTWO
-
RLXXFRELX PLC
RLXXF
-
OXSQ
-
WFAFYWesfarmers Limited
WFAFY
-
ACGBY
-
STNStantec Inc.
STN
-
000638
-
INA